<DOC>
	<DOCNO>NCT03064269</DOCNO>
	<brief_summary>This study evaluate safety efficacy Chimeric antigen receptor T cell ( CAR-T ) treat central nervous system B-cell acute lymphocytic leukemia .</brief_summary>
	<brief_title>CAR-T Therapy Central Nervous System B-cell Acute Lymphocytic Leukemia</brief_title>
	<detailed_description>CNS leukemia define unequivocal evidence leukemic blast cerebrospinal fluid cytology flow cytometry ; cranial palsy nonhemorrhagic mass see cranial compute tomography magnetic resonance image infiltration leukemia cell</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>1 . Patients CD19 positive central nervous system Bcell acute lymphocytic leukemia 2 . ALT/ AST 《 3x normal 3 . Creatinine 《 3x normal 4 . Age:1060 . 5 . Signed informed consent 1 . Active hepatitis B , hepatitis C HIV infection 2 . Uncontrolled active infection 3 . Pregnancy breastfeed woman 4 . Survival le four week</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CNS B cell acute lymphocytic leukemia</keyword>
</DOC>